Agilent acquire Aurora SFC Systems
Agilent Technologies (Santa Clara, California, USA) has purchased the supercritical fluid chromatography company Aurora SFC Systems, Inc (Redwood, California, USA).
Agilent Technologies (Santa Clara, California, USA) has purchased the supercritical fluid chromatography company Aurora SFC Systems, Inc (Redwood, California, USA).
Aurora and Agilent have been partners for the past two years. Aurora’s technology is embedded into several Agilent systems and is available as part of an upgrade option. Acquiring Aurora SFC assets enables Agilent to offer these products as fully integrated, single-vendor SFC solutions.
Patrick Kaltenbach, vice president and general manager of Agilent’s liquid phase separations business, commented: “We valued the partnership we had with Aurora SFC Systems and are excited to bring this technology and expertise into Agilent. The deployment of orthogonal separation techniques has gained significant importance in liquid phase separations as regulatory agencies increasingly demand comprehensive results.”
For more information please visit ref="http://www.agilent.com">www.agilent.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
